MX2008009719A - Nueva sal de citrato de un derivado de indol y su uso farmaceutico. - Google Patents

Nueva sal de citrato de un derivado de indol y su uso farmaceutico.

Info

Publication number
MX2008009719A
MX2008009719A MX2008009719A MX2008009719A MX2008009719A MX 2008009719 A MX2008009719 A MX 2008009719A MX 2008009719 A MX2008009719 A MX 2008009719A MX 2008009719 A MX2008009719 A MX 2008009719A MX 2008009719 A MX2008009719 A MX 2008009719A
Authority
MX
Mexico
Prior art keywords
disease
salt
dementia
pyridin
morpholin
Prior art date
Application number
MX2008009719A
Other languages
English (en)
Spanish (es)
Inventor
Ratan Bhat
Tesfai Sebhatu
Anna-Lena Berg
Erica Staahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2008009719A publication Critical patent/MX2008009719A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2008009719A 2006-02-02 2007-01-31 Nueva sal de citrato de un derivado de indol y su uso farmaceutico. MX2008009719A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76455106P 2006-02-02 2006-02-02
PCT/SE2007/000086 WO2007089191A1 (en) 2006-02-02 2007-01-31 New citrate salt of an indole derivative and its pharmaceutical use

Publications (1)

Publication Number Publication Date
MX2008009719A true MX2008009719A (es) 2008-09-04

Family

ID=38327680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008009719A MX2008009719A (es) 2006-02-02 2007-01-31 Nueva sal de citrato de un derivado de indol y su uso farmaceutico.

Country Status (24)

Country Link
US (2) US8008294B2 (enExample)
EP (1) EP1981869A4 (enExample)
JP (1) JP2009525324A (enExample)
KR (1) KR20080098022A (enExample)
CN (2) CN101378754A (enExample)
AR (1) AR059225A1 (enExample)
AU (1) AU2007210336B2 (enExample)
BR (1) BRPI0706745A2 (enExample)
CA (1) CA2641900A1 (enExample)
EC (1) ECSP088647A (enExample)
IL (1) IL192888A0 (enExample)
MX (1) MX2008009719A (enExample)
MY (1) MY146102A (enExample)
NO (1) NO20083784L (enExample)
NZ (1) NZ570849A (enExample)
PE (1) PE20090192A1 (enExample)
RU (1) RU2415137C2 (enExample)
SA (1) SA07280004B1 (enExample)
SG (1) SG169381A1 (enExample)
TW (1) TW200800977A (enExample)
UA (1) UA94251C2 (enExample)
UY (1) UY30126A1 (enExample)
WO (1) WO2007089191A1 (enExample)
ZA (1) ZA200806725B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
US8101750B2 (en) * 2007-04-18 2012-01-24 Astrazeneca Ab Process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile 701
EP2183247B1 (en) * 2007-07-30 2012-05-16 AstraZeneca AB New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl]1h- indole- 5 -carbonitrile citrate
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
TW202204348A (zh) * 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785109B1 (ko) 2001-04-05 2007-12-12 토렌트 파마슈티칼스 리미티드 노화 관련 및 당뇨병 혈관성 합병증에 사용되는 헤테로사이클릭 화합물
JP2003009588A (ja) 2001-06-20 2003-01-10 Toshiba Corp 車両連続運転装置用インバータ装置
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
EP1653970A4 (en) * 2003-08-13 2008-10-15 Novartis Vaccines & Diagnostic GSK-3 HEMMER AND ITS USES
JP5507049B2 (ja) 2004-12-30 2014-05-28 アステックス、セラピューティックス、リミテッド 医薬品
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات

Also Published As

Publication number Publication date
RU2008131906A (ru) 2010-03-10
SG169381A1 (en) 2011-03-30
US20090023732A1 (en) 2009-01-22
AR059225A1 (es) 2008-03-19
TW200800977A (en) 2008-01-01
RU2415137C2 (ru) 2011-03-27
UY30126A1 (es) 2007-09-28
US20070203137A1 (en) 2007-08-30
BRPI0706745A2 (pt) 2011-04-05
KR20080098022A (ko) 2008-11-06
CA2641900A1 (en) 2007-08-09
ZA200806725B (en) 2009-07-29
CN101378754A (zh) 2009-03-04
WO2007089191A1 (en) 2007-08-09
IL192888A0 (en) 2009-02-11
AU2007210336B2 (en) 2011-03-24
EP1981869A1 (en) 2008-10-22
US8008294B2 (en) 2011-08-30
NO20083784L (no) 2008-10-13
JP2009525324A (ja) 2009-07-09
AU2007210336A1 (en) 2007-08-09
NZ570849A (en) 2011-01-28
CN101379053A (zh) 2009-03-04
ECSP088647A (es) 2008-08-29
UA94251C2 (ru) 2011-04-26
PE20090192A1 (es) 2009-03-20
EP1981869A4 (en) 2010-08-25
SA07280004B1 (ar) 2011-10-29
MY146102A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
EP1575938B1 (en) Compounds having selective inhibiting effect at gsk3
WO2007120102A1 (en) New substituted oxindole derivatives
JP5424256B2 (ja) アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼｉｖの阻害剤としての用途
EP1458395B1 (en) Medical use of gsk3-inhibiting oxindole derivatives
JP2010535200A (ja) ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］−１ｈ−インドール−５−カルボニトリル・クエン酸塩の新しい結晶形態
US20120101132A1 (en) New Substituted Oxindole Derivative
RU2415137C2 (ru) Цитратная соль производного индола, способ ее получения, ее применение и фармацевтическая композиция на ее основе
US20090018130A1 (en) Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid
JP2009528344A (ja) インドール誘導体の新規な塩及び医薬におけるその使用
HK1129382A (en) New citrate salt of an indole derivative and its pharmaceutical use
WO2012050517A1 (en) Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
WO2024059659A1 (en) Cycloalkyl carboxylic acid derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
HK1142070A (en) Compounds having selective inhibiting effect at gsk3
HK1080856B (en) Compounds having selective inhibiting effect at gsk3

Legal Events

Date Code Title Description
FG Grant or registration